| Keywords: |
cancer chemotherapy; hydroxyurea; cisplatin; doxorubicin; fluorouracil; dose response; antineoplastic agents; methotrexate; brain tumor; glioma; brain neoplasms; animal; antineoplastic combined chemotherapy protocols; cell line; combination chemotherapy; drug resistance; dose-response relationship, drug; carmustine; lomustine; procarbazine; central nervous system; kinetics; cerebrospinal fluid; drug response; blood brain barrier; blood-brain barrier; infusions, intra-arterial; rats; karyotyping; mannitol; therapy; teniposide; pharmacokinetics; survey; drug cerebrospinal fluid level; diaziquone; tumor stem cell assay; podophyllotoxin; semustine; mitolactol; nimustine; carbon radioisotopes; human; leucine c 14; dianhydrogalactitol; blood and hemopoietic system; 2 amino 2 methylpropionic acid c 14; spiromustine; 1 (2 chloroethyl) 3 (2,6 dioxo 1 piperidyl) 1 nitrosourea; cancer cell population heterogeneity; methotrexate c 14; uridine h 3
|
